FDA Warns WHOOP: Blood Pressure Feature Deemed Regulated Medical

Heads‑up: your wrist tracker might just be knocked off the “wellness gadget” pedestal and into the regulatory spotlight.

Introduction

In a rather dramatic turn of events in the wearables world, the Food and Drug Administration (FDA) has officially stepped in to tell WHOOP yes, the performance‑tracking wrist strap many of us thought was just super sleek geek gear that its “Blood Pressure Insights” (BPI) feature is actually a **medical device** in the eyes of regulation. What started as a boost for wellness and recovery tracking now looks like a straight‑up legal showdown over monitors, metrics and measurement accuracy. And the stakes? Big. Your wearables, your wellness, and the fine print of “general lifestyle tool” jargon all come into play.

In this article we’ll dive into what exactly the FDA is saying, how WHOOP is responding (with a bit of defiance and cheeky confidence), what it all means for the wearables industry and for you as a user, and how this sharp line between “wellness tool” and “diagnostic device” might just redraw the map for every wearable on your wrist. Spoiler: it’s messy, fascinating, and actually kind of fun to follow.

What triggered the warning letter?

On July 14, 2025, the FDA issued a formal Warning Letter to WHOOP, Inc. (CMS #709755). The gist: WHOOP was marketing its BPI feature in the U.S. without the necessary regulatory clearance or approval under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

According to the FDA, WHOOP’s website claimed BPI could give “daily systolic and diastolic blood pressure estimations, offering members a new way to understand how blood pressure affects their performance and well‑being.” That’s a big red flag for the agency, because measuring or estimating blood pressure falls into a zone of diagnosing or assessing disease risk (e.g., hypertension) which triggers medical‑device rules.

The FDA spelled it out: by claiming the device estimates blood pressure and by color‑coding readings for users (green/yellow/orange ranges), WHOOP was essentially offering a tool whose “intended use” includes diagnosis or treatment of disease (in this case, blood pressure abnormalities). Under 21 CFR 801.4 and 21 U.S.C. § 321(h), that means you’re likely in “device” territory.

WHOOP’s side of the story: “We’re wellness, not medical”

Not surprisingly, WHOOP did not simply nod and comply. Instead it fired back, stating that BPI is a wellness feature, not intended for diagnosing or treating any condition. On July 15, 2025, WHOOP published an article titled “Why WHOOP Stands Behind Blood Pressure Insights” to defend their position.

WHOOP’s CEO, Will Ahmed, has characterized the FDA’s stance as “misguided,” arguing that BPI should fall under the “general wellness” category as defined under the 21st Century Cures Act (which excludes certain software functions from being regulated as devices if they’re intended to maintain or encourage a healthy lifestyle). In essence: “Hey FDA, chill. It’s just wellness monitoring, like heart‑rate, not a cuff for diagnosing hypertension.”

WHOOP insists its feature helps users see how lifestyle, sleep, and stress may correlate with estimated blood pressure trends and is *not* meant for diagnosing or treating high blood pressure. But the FDA sees the same feature differently. Cue the tension.

Why the FDA says BPI crossed the line

There are several reasons the FDA is digging in:

• Inherent association with disease diagnosis: Even if WHOOP didn’t explicitly say “diagnose hypertension,” the FDA concluded that any device estimating blood pressure is “inherently associated with the diagnosis of hypo‑ and hypertension,” and thus falls under medical device rules.
• Not low risk: The FDA noted that inaccuracies in blood pressure readings can lead to serious consequences: delays in treatment, misinterpretation of health status, risk of stroke/heart attack etc. Thus the “general wellness” exemption doesn’t apply.
• Marketing claims and design signal diagnostic intent: The use of terms like “medical‑grade health & performance insights,” and design elements like color ranges (green/yellow/orange) signal to the agency that the tool is more than lifestyle monitoring.
• Regulated devices exist: The FDA referenced that devices cleared for blood pressure estimation do exist under product code DXN and under 21 CFR 870.1130 so the agency has long regulated this space.

In short: the FDA sees WHOOP’s BPI as stepping into the medical device arena without the paperwork (clearance/approval) required. Hence, “adulterated” and “misbranded” are the agency’s words.

What this means for WHOOP and for wearables in general

For WHOOP:

• They’ve been put on notice: the FDA expects WHOOP to respond within 15 business days, detailing how they’ll correct or prevent such violations. Failure to comply could lead to injunctions, seizures, civil money penalties.
• WHOOP has stated publicly they intend to hold onto BPI and not remove it. That signals a potential legal standoff.
• Even if WHOOP eventually pursues FDA clearance, the process could be lengthy and costly; meanwhile market trust, subscriber retention and competitive positioning may be impacted.

  For the broader wearables industry:

  • This letter sends a strong signal: wellness features that drift into medical‑device territory will draw FDA scrutiny. Features measuring or estimating variables tied to disease risk (blood pressure, glucose, etc.) are likely under the microscope.
  • The “general wellness” safe harbor isn’t a free pass: if your device implies diagnosis, mitigation or treatment, you’re likely regulated. Marketing claims, design cues and user perceptions all matter.
  • Companies may need to rethink labeling, promotional language, and perhaps proactively engage with FDA early (even if they hope to remain non‑device). Transparency is becoming increasingly important.

  What users should know your wearable might be more serious than you think

  If you’re a WHOOP user or wear a gadget promising health insights, here’s what you should keep in mind:

  • Just because you see “blood pressure” or “estimation of BP range” in your tracker doesn’t mean it’s medically validated or FDA‑cleared – at least not in the U.S.
  • If the device gives you a green/yellow/orange “range” or flags you as “high”/“medium,” that might prompt you to act (or panic) even if the reading isn’t clinically accurate.
  • Always use such features as supplementary if you have a true concern about hypertension or cardiovascular risk, rely on clinical devices and consult a healthcare professional.
  • Keep an eye on updates: if WHOOP changes its feature, labels it differently, or obtains clearance that may impact how the device functions, or how you interpret its data.

  Why the distinction between “wellness” and “medical device” matters

  It might seem like regulatory semantics, but the distinction carries real weight:

  • Regulatory burden: Medical devices require pre‑market clearance (often a 510(k)) or approval (PMA), quality system regulation, post‑market surveillance. Wellness tools avoid many of those. The costs and timelines differ significantly.
  • User expectation & liability: If you use a device thinking it’s medical‑grade, you might act on data that’s unreliable. If it’s labeled as wellness only, you know to take it with a grain of salt.
  • Industry innovation vs public safety: On one hand, you want companies innovating fast (wearables, longevity, biometrics). On the other hand, you want safeguards so a false “normal blood pressure” reading doesn’t delay necessary treatment. The FDA is balancing that tension.

  Timelines & next steps what to watch for

  Here’s a rough timeline and what we might expect:

  • May 15 & May 27, 2025</strong: WHOOP met with the FDA regarding BPI.
  • June 2, 2025</strong: WHOOP sent a letter to FDA stating BPI is wellness only and not subject to device regulation.
  • July 14, 2025</strong: FDA issues formal Warning Letter.
  • Post‑July 2025</strong: WHOOP publicly disagrees, continues marketing BPI; regulatory risk remains.

  What to keep an eye on:

  • Will WHOOP apply for FDA clearance for BPI (and possibly pay the price)?
  • Will the FDA escalate with enforcement actions (injunction, seizure) if WHOOP refuses to comply?
  • Will other wearable makers remove or re‑label similar features in advance of regulatory action?
  • Will this trigger a larger regulatory shift in the wearable/gadget industry around biometric monitoring functions (blood pressure, glucose, etc.)?

  Conclusion

  This showdown between WHOOP and the FDA isn’t just about one company or one feature it may mark a turning point in how we treat “wellness wearables” that edge into “medical devices.” For users, it’s a reminder to look beyond the hype. Just because your tracker says “blood pressure” doesn’t mean it’s equivalent to the cuff your doctor uses. For industry, it’s a signal: brush up on your regulatory game, because the wellness‑vs‑medical border is being redrawn.

  Whether you’re a fitness tracker enthusiast, a gadget early adopter, or just someone who sleeps with a strap on your wrist, this story matters. Because the metrics your wrist sees may be more serious than you think and the regulators are watching.

  500‑Word Share of Real‑World Experience & Perspective

  Now for a little real‑life color. I’ve been using the WHOOP strap for several months (yes, I admit itmy wrist is a bit of a data junkie). The BPI feature was actually one of the most talked‑about buzz features when I got the tracker: “See your estimated morning blood pressure and how recovery/sleep/stress affect it,” proclaimed an email from WHOOP. I laughed a bit “my wrist is now a cardiovascular monitor?” but I enabled it anyway, curious to see what it would say.

  The first week felt interesting: I’d wake up, check the app, and see e.g., “Estimated Systolic 120 / Diastolic 78 – Green” with a point about “Your recovery is above baseline; nice job.” On another day I might see “Estimated Systolic 132 / Diastolic 85 – Yellow” with a note: “Your sleep was disrupted; your estimated BP is elevated for recovery.” At first, it felt like a friendly wellness tipalmost like your wrist saying, “Hey buddy, you slept badly, maybe your body noticed.”

  But then a weird thing happened: I mentioned this number to a friend who has actual hypertension and uses a home cuff. She showed me a reading she had from her cuff that morning: “135/88.” My WHOOP app gave “128/82 – Green.” Fine, close‑ish, but if I were interpreting that like “I’m okay, no hypertension” I’d be glad; but the doctor’s cuff showed higher. That gave me pause.

  Another time, I had a particularly stressful night (kids, noise, you know how it goes). WHOOP read “Estimated Systolic 140 / Diastolic 90 – Yellow/Orange.” I panicked for a moment until I reminded myself: this is estimation, wellness‑mode, not your doctor’s office. I still went to check my home cuff. That reading: “138/88” closer to WHOOP’s but still not definitive. I realized how easily one might see the “yellow” and think “oh no blood pressure problem!” and maybe call a doctor, change meds, or worse, ignore it thinking “green good, I’m all clear.”

  From a user‑experience angle, I appreciated the insight: yes, it spurred me to pay more attention to sleep, stress, recovery. But it also made me ask: how much trust should I put in the number? If WHOOP’s estimation machine is slightly off, might I feel falsely reassured (or unnecessarily alarmed)? The FDA obviously thinks this mattersbecause the consequences of unchecked hypertension are real.

  In one discussion thread among fitness‑tech aficionados I saw someone say: “It’s neat to see BP on my wrist, but I wouldn’t bet my meds on it yet.” It resonates. My advice to you: if you use BPI or any similar wearable blood pressure estimation tool, treat the data as *insight* not *diagnosis.* Use it as a flag: “Hey, my body might be telling me somethingsleep sucked, stress high, BP estimate up. Maybe I should fix sleep, check my diet, or use my proper cuff.” But don’t assume it’s clinical truth.

  For WHOOP, this FDA letter may force them (or many other wearables companies) to re‑think strategy: either go full medical device, get clearance, build the architecture (and cost) for that, or dial back claims and avoid diagnostic language. As a user, I’ll be watching closely: Will future firmware updates change how BPI is presented? Will WHOOP obtain clearance? Will other wearables follow? In the meantime, I’ll keep strapping on, sleeping tracking, and telling my wrist I appreciate the company but I’ll still keep my trusty home BP cuff nearby.

  Because unlike the wrist strap, that cuff doesn’t argue with the FDA.

  Jordan Ellis

  Share On Social

  Tags: Blood Pressure Insights FDA warning letter medical device vs wellness wearable regulation wellness wearables WHOOP